PEOPLE ON THE MOVE
Xencor
Biopharma company Xencor has appointed Wayne Saville (pictured) VP of clinical oncology and Mark Lotz VP of regulatory affairs.
The Monrovia, California-based company develops mAbs for cancers and autoimmune and allergic diseases.
"The addition of Mr Lotz and Dr Saville add expertise and substantial depth to Xencor's drug development team as we move more XmAb candidates forward into clinical development," said Bassil Dahiyat, Xencor CEO.
"Mark's wealth of experience in biopharma regulatory affairs and quality assurance strategy is of tremendous value as we initiate clinical testing of XmAb5871 in the rare IgG4-Related Disease this year and continue to advance XmAb7195 and the rest of our pipeline.
“In addition, Wayne's expertise in clinical oncology, translational research and medical affairs will be particularly valuable as we progress our bispecific oncology candidates such as XmAb14045.”
Mark Lotz has worked in regulatory and quality roles at Abbott, Amylin, Isis, MediciNova, Elan, IASO, and most recently Samumed.
Wayne Saville was previously VP of clinical development oncology at Tocagen. He has also worked at Genoptix (acquired by Novartis), Amgen, Biogen Idec and Idec Pharmaceuticals.
